Promising malaria vaccine candidates enter key trial in african children
NCT ID NCT07183371
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two experimental malaria vaccines in 360 children aged 5 to 36 months in Burkina Faso, a country where malaria is common. The vaccines aim to prevent malaria caused by the Plasmodium falciparum parasite. Researchers will check how safe the vaccines are, how well they trigger the immune system, and whether they reduce cases of malaria over six months after the final dose.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut de Recherche en Sciences de la Sante - Clinical Research Unit of Nanoro (IRSS-URCN)
Nanoro, Burkina Faso
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill make your blood deadly to malaria mosquitoes?
- Can a new vaccine stop malaria in its tracks?
- Can a new malaria vaccine slash childhood cases? a massive real-world test seeks answers.
- One shot, six months of malaria shield? a new trial tests a powerful antibody in children
- School health rooms and trained teachers: a new hope for Zambia's children?
- Experimental malaria vaccine aims to block parasite growth